IPSEF:OTC-Ipsen S.A (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 125.37

Change

0.00 (0.00)%

Market Cap

USD 10.37B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

-4.35 (-2.78%)

USD 71.76B
MKKGY Merck KGaA ADR

-1.28 (-3.99%)

USD 71.76B
TKPHF Takeda Pharmaceutical Co. Ltd.

-0.83 (-3.10%)

USD 44.53B
HLNCF Haleon plc

+0.01 (+0.23%)

USD 43.64B
TEVJF Teva Pharmaceutical Industries..

+1.86 (+10.33%)

USD 20.99B
SDZXF Sandoz Group AG

N/A

USD 19.52B
SDZNY Sandoz Group AG

-0.92 (-2.02%)

USD 19.38B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 13.26B
SWOBY Swedish Orphan Biovitrum AB (p..

+1.98 (+13.01%)

USD 10.70B
IPSEY Ipsen SA ADR

+0.51 (+1.77%)

USD 10.31B

ETFs Containing IPSEF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.02% 65% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.02% 65% D 65% D
Trailing 12 Months  
Capital Gain 6.53% 59% D- 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.53% 59% D- 55% F
Trailing 5 Years  
Capital Gain 22.23% 84% B 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.23% 84% B 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 9.83% 62% D 53% F
Dividend Return 11.03% 62% D 51% F
Total Return 1.19% 48% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 21.83% 95% A 84% B
Risk Adjusted Return 50.51% 96% N/A 85% B
Market Capitalization 10.37B 97% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector